Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Remdesivir  COVID-19 treatment studies for Remdesivir  C19 studies: Remdesivir  Remdesivir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality, mild/moderate 11% Improvement Relative Risk Mortality, severe 24% c19early.org/s Hartantri et al. Remdesivir for COVID-19 LATE Is late treatment with remdesivir beneficial for COVID-19? Retrospective study in Indonesia (March - December 2020) No significant difference in mortality Hartantri et al., The Lancet Regional Health - S.., doi:10.1016/j.lansea.2023.100167 Favors remdesivir Favors control
Clinical and treatment factors associated with the mortality of COVID-19 patients admitted to a referral hospital in Indonesia
Hartantri et al., The Lancet Regional Health - Southeast Asia, doi:10.1016/j.lansea.2023.100167
Hartantri et al., Clinical and treatment factors associated with the mortality of COVID-19 patients admitted to a referral.., The Lancet Regional Health - Southeast Asia, doi:10.1016/j.lansea.2023.100167
Feb 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 689 hospitalized patients in Indonesia, showing no significant difference in mortality with remdesivir treatment.
[Gérard, Wu, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
risk of death, 11.0% lower, HR 0.89, p = 0.84, adjusted per study, mild/moderate, multivariable, Cox proportional hazards.
risk of death, 24.0% lower, HR 0.76, p = 0.53, adjusted per study, severe, multivariable, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hartantri et al., 9 Feb 2023, retrospective, Indonesia, peer-reviewed, 10 authors, study period 1 March, 2020 - 31 December, 2020.
Contact: b.alisjahbana@unpad.ac.id.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperRemdesivirAll
Abstract: Journal Pre-proof Clinical and treatment factors associated with the mortality of COVID-19 patients admitted to a referral hospital in Indonesia Yovita Hartantri, Josephine Debora, Leonardus Widyatmoko, Gezy Giwangkancana, Hendarsyah Suryadinata, Evan Susandi, Elisabeth Hutajulu, Assica Permata Amalya Hakiman, Yesy Pusparini, Bachti Alisjahbana PII: S2772-3682(23)00027-6 DOI: https://doi.org/10.1016/j.lansea.2023.100167 Reference: LANSEA 100167 To appear in: The Lancet Regional Health - Southeast Asia Received Date: 19 May 2022 Revised Date: 31 January 2023 Accepted Date: 1 February 2023 Please cite this article as: Hartantri Y, Debora J, Widyatmoko L, Giwangkancana G, Suryadinata H, Susandi E, Hutajulu E, Amalya Hakiman AP, Pusparini Y, Alisjahbana B, Clinical and treatment factors associated with the mortality of COVID-19 patients admitted to a referral hospital in Indonesia, The Lancet Regional Health - Southeast Asia (2023), doi: https://doi.org/10.1016/j.lansea.2023.100167. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2023 The Author(s). Published by Elsevier Ltd. Clinical and treatment factors associated with the mortality of COVID-19 patients admitted to a referral hospital in Indonesia Yovita Hartantri1, Josephine Debora1, Leonardus Widyatmoko2, Gezy Giwangkancana3, Hendarsyah Suryadinata1, of Evan Susandi1, ro Elisabeth Hutajulu1, -p Assica Permata Amalya Hakiman4, Yesy Pusparini5, lP re Bachti Alisjahbana1,4 1Internal Medicine Department, Hasan Sadikin General Hospital, Faculty of Medicine, Pathology Department, Hasan Sadikin General Hospital, Faculty of Medicine, ur 2Clinical na Universitas Padjadjaran, Bandung, Indonesia Universitas Padjadjaran, Bandung, Indonesia Jo 3Anesthesiology and Intensive Care Department, Hasan Sadikin General Hospital, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia 4Research Center for Care and Control of Infectious Diseases (RC3ID), Universitas Padjadjaran, Bandung, Indonesia 5Hasan Sadikin General Hospital, Bandung, Indonesia Corresponding author: Bachti Alisjahbana Address: Internal Medicine Department, Hasan Sadikin General Hospital, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia. Jl. Pasteur No. 38, Bandung 40161, West Java, Indonesia. Email: b.alisjahbana@unpad.ac.id 1 Summary Background Indonesia had the second-highest number of COVID-19 cases and deaths in South-East Asia. We aimed to determine the factors associated with this mortality and the effect of the recommended COVID-19 treatment regimen during the first 10 months of the epidemic. Methods This was a retrospective cohort study using secondary data from medical records. In total, 689 adult COVID-19 inpatients hospitalized between March and December 2020 were of enrolled. Clinical characteristics, laboratory parameters, and treatments were analyzed by ro survival outcome. Kaplan-Meier statistics were used to estimate..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit